Desjardins Paul, Alvarado Fabian, Gil Martha, González Manuel, Guajardo Rogelio
Desjardins Associates, LLC, Maplewood, New Jersey.
Rutgers School of Dental Medicine, Newark, New Jersey, USA.
Pain Med. 2020 Oct 1;21(10):2447-2457. doi: 10.1093/pm/pnaa124.
To evaluate the analgesic efficacy and safety of tramadol hydrochloride/diclofenac sodium fixed-dose combination 25 mg/25 mg (FDC 25/25) and 50 mg/50 mg (FDC 50/50) vs tramadol 50 mg (T50) and diclofenac 50 mg (D50) monotherapies in acute postoperative dental pain.
Eight sites across Mexico.
Adults (N = 829) with moderate to severe pain after third molar extraction.
Prospective, randomized, double-blind, diclofenac- and tramadol-controlled, parallel-group, noninferiority, phase 3 trial.
Subjects were randomized to receive three doses (one every eight hours) of oral FDC 25/25, FDC 50/50, T50, or D50 over a 24-hour period. Pain intensity and pain relief were evaluated frequently over the 24 hours postdose. Secondary measures included peak pain relief, onset, and duration of effect. The primary objective was to compare the analgesic efficacy and safety of FDC 50/50 or analgesic noninferiority of FDC 25/25 vs D50 or T50. The primary efficacy end point was total pain relief over four hours after dose 1 (TOTPAR4).
TOTPAR4 scores showed that FDC 25/25 was noninferior (P < 0.0001, delta = 1.5) and FDC 50/50 was superior (P < 0.0001) to the individual components. All secondary efficacy measures supported these results. The safety profile of FDC 25/25 and FDC 50/50 was consistent with the known safety profile of D50 and T50 monotherapies, with no unexpected safety findings observed.
Tramadol/diclofenac FDC 25/25 and FDC 50/50 provide superior analgesia for acute pain after third molar extraction than either of the individual components. Minor adverse effects appeared to be related to the higher doses of tramadol.
评估盐酸曲马多/双氯芬酸钠固定剂量组合25mg/25mg(FDC 25/25)和50mg/50mg(FDC 50/50)与曲马多50mg(T50)和双氯芬酸50mg(D50)单一疗法用于急性术后牙疼痛的镇痛疗效和安全性。
墨西哥的八个地点。
拔除第三磨牙后有中度至重度疼痛的成年人(N = 829)。
前瞻性、随机、双盲、双氯芬酸和曲马多对照、平行组、非劣效性3期试验。
受试者被随机分配在24小时内接受三剂(每8小时一剂)口服FDC 25/25、FDC 50/50、T50或D50。在给药后24小时内频繁评估疼痛强度和疼痛缓解情况。次要指标包括最大疼痛缓解、起效时间和作用持续时间。主要目的是比较FDC 50/50的镇痛疗效和安全性,或FDC 25/25与D50或T50相比的镇痛非劣效性。主要疗效终点是第1剂后4小时内的总疼痛缓解(TOTPAR4)。
TOTPAR4评分显示,FDC 25/25具有非劣效性(P < 0.0001,差值 = 1.5),FDC 50/50优于单一成分(P < 0.0001)。所有次要疗效指标均支持这些结果。FDC 25/25和FDC 50/50的安全性与D50和T50单一疗法已知的安全性一致,未观察到意外的安全性发现。
曲马多/双氯芬酸FDC 25/25和FDC 50/50在拔除第三磨牙后的急性疼痛中提供的镇痛效果优于单一成分中的任何一种。轻微不良反应似乎与较高剂量的曲马多有关。